HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo's Omega Pharma Struggles In 2018 As It Continues To Restructure And Divest

Executive Summary

Perrigo's Europe-focused consumer health business Omega Pharma found sales growth hard to come by in 2018 as the group worked hard to right size the organization. While it still has a way to go to completely turnaround Omega, Perrigo is starting to see these interventions pay off, with profits up for the 12 months. 

You may also be interested in...



International Business Floats Perrigo Q2 Sales As Market Uncertainties Cloud Americas Region

OTC drug private label/store brand giant reports April-June overall net sales of $981m, up 3.4%. As its Americas business organic sales slipped 1.4% to $622m, international business sales grew 11.7% to $359m.

Perrigo's Q1 Results Offer Scant Support To Promote Its 'Self-Care' Turnaround

President and CEO Murray Kessler attempts to temper expectations before investor day on May 9 saying Perrigo's turnaround under strategy implemented after he joined firm in November is in its early days. Private label leader, however, will report another step in its move to return to being consumer product-focused: agreement to sell its animal health business to PetIQ for $185m cash.

IRS Notice Pushes Perrigo's Potential Tax Debt From Move To Ireland Close To $3bn

IRS tax assessment for 2013, the year Perrigo acquired Dublin-based Elan, adds another cloud to OTC private label giant's outlook as it prepares to present plans for accelerating growth for its long-slumping consumer health business in the US and Europe at a March 9 investor day conference. Perrigo shares dropped more than 9% in early trading after IRS notice became known to investors before inching upward and ending at $47.92, down 6.8% from the previous day's close.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS148728

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel